Boston Scientific Corp. has posted 61 percent increase in profits for the second quarter, beating Wall Street expectations and pushing shares up by 7 percent.

Boston Scientific Corp. gave the credit for the better-than-expected results to strong demand for its heart products.

For the quarter ended in June, company's net income increased to $158 million or 10 cents per share, from $98 million, or 7 cents per share, a year earlier.

Revenue climbed to $2.07 billion owing to a jump in sales of stents and implantable devices to manage the rhythm of the heart.  

Excluding special items, company's earning stood at $297 million or 20 cents per share.

Earlier, analysts had projected earnings before items of 14 cents per share.

Company's chief executive, Ray Elliott said, "We delivered sales and earnings at the high end of our guidance range with almost all businesses and regions reporting solid results."

In the recent trading, Boston Scientific shares closed at $11, up 6.8 percent on NYSE.